Does malignant stroma increase luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling?
We provide evidence that Luminal breast cancer cells can be targeted by the PDGF signaling pathway leading to estrogen-independent proliferation and angiogenesis. We speculate that stroma-directed therapies, including anti-PDGFR agents like Imatinib, may be useful in combination with other therapies for treatment of luminal cancers.
While this program has achieved its objectives, there are a few issues that need to be considered by similar programs: the post-program stage of patient follow-up by general practitioners; the geographical disadvantage of those living outside regional centres to access the service; enhancing the primary prevention aspect of the program; adapting the program to the needs of Aboriginal clients; facilitating evaluations by resourcing and training program staff in computer skills.